Promising Molecular Targets for the Targeted Therapy of Biliary Tract Cancers: An Overview

References

• de Groen PC, Gores GJ, LaRusso NF, Gunderson LL, Nagorney DM. Biliary tract cancers. N Engl J Med. 1999;341(18):1368–1378. doi:10.1056/NEJM199910283411807
   PubMed Web of Science ®Google Scholar
• Lombardi P, Marino D, Fenocchio E, Chila G, Aglietta M, Leone F. Emerging molecular target antagonists for the treatment of biliary tract cancer. Expert Opin Emerg Drugs. 2018;23(1):63–75. doi:10.1080/14728214.2018.1444749
   PubMed Web of Science ®Google Scholar
• Mosconi S, Beretta GD, Labianca R, Zampino MG, Gatta G, Heinemann V. Cholangiocarcinoma. Crit Rev Oncol Hematol. 2009;69(3):259–270. doi:10.1016/j.critrevonc.2008.09.008
   PubMed Web of Science ®Google Scholar
• Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359–86. doi:10.1002/ijc.29210
   PubMed Web of Science ®Google Scholar
• Torre LA, Siegel RL, Islami F, Bray F, Jemal A. Worldwide burden of and trends in mortality from gallbladder and other biliary tract cancers. Clin Gastroenterol Hepatol. 2018;16(3):427–437. doi:10.1016/j.cgh.2017.08.017
   PubMed Web of Science ®Google Scholar
• Shaib YH, Davila JA, McGlynn K, El-Serag HB. Rising incidence of intrahepatic cholangiocarcinoma in the United States: a true increase? J Hepatol. 2004;40(3):472–477. doi:10.1016/j.jhep.2003.11.030
   PubMed Web of Science ®Google Scholar
• Chapman RW. Risk factors for biliary tract carcinogenesis. Ann Oncol. 1999;10(Suppl 4):308–311. doi:10.1093/annonc/10.suppl_4.S308
   PubMed Web of Science ®Google Scholar
• Charbel H, Al-Kawas FH. Cholangiocarcinoma: epidemiology, risk factors, pathogenesis, and diagnosis. Curr Gastroenterol Rep. 2011;13(2):182–187. doi:10.1007/s11894-011-0178-8
   PubMedGoogle Scholar
• Khan SA, Toledano MB, Taylor-Robinson SD. Epidemiology, risk factors, and pathogenesis of cholangiocarcinoma. HPB (Oxford). 2008;10(2):77–82. doi:10.1080/13651820801992641
   PubMed Web of Science ®Google Scholar
• Shigeyasu K, Tanakaya K, Nagasaka T, et al. Early detection of metachronous bile duct cancer in Lynch syndrome: report of a case. Surg Today. 2014;44(10):1975–1981. doi:10.1007/s00595-013-0669-3
   PubMed Web of Science ®Google Scholar
• Golan T, Raitses-Gurevich M, Kelley RK, et al. Overall survival and clinical characteristics of BRCA-associated cholangiocarcinoma: a multicenter retrospective study. Oncologist. 2017;22(7):804–810. doi:10.1634/theoncologist.2016-0415
   PubMed Web of Science ®Google Scholar
• Sriamporn S, Pisani P, Pipitgool V, Suwanrungruang K, Kamsa-ard S, Parkin DM. Prevalence of Opisthorchis viverrini infection and incidence of cholangiocarcinoma in Khon Kaen, Northeast Thailand. Trop Med Int Health. 2004;9(5):588–594. doi:10.1111/j.1365-3156.2004.01234.x
   PubMed Web of Science ®Google Scholar
• Harrington J, Carter L, Basu B, Cook N. Drug development and clinical trial design in pancreatico-biliary malignancies. Curr Probl Cancer. 2018;42(1):73–94. doi:10.1016/j.currproblcancer.2018.01.003
   PubMed Web of Science ®Google Scholar
• Everhart JE, Ruhl CE. Burden of digestive diseases in the United States Part III: liver, biliary tract, and pancreas. Gastroenterology. 2009;136(4):1134–1144. doi:10.1053/j.gastro.2009.02.038
   PubMed Web of Science ®Google Scholar
• Horgan AM, Amir E, Walter T, Knox JJ. Adjuvant therapy in the treatment of biliary tract cancer: a systematic review and meta-analysis. J Clin Oncol. 2012;30(16):1934–1940. doi:10.1200/JCO.2011.40.5381
   PubMed Web of Science ®Google Scholar
• Endo I, Gonen M, Yopp AC, et al. Intrahepatic cholangiocarcinoma: rising frequency, improved survival, and determinants of outcome after resection. Ann Surg. 2008;248(1):84–96. doi:10.1097/SLA.0b013e318176c4d3
   PubMed Web of Science ®Google Scholar
• Jiang W, Zeng ZC, Tang ZY, et al. A prognostic scoring system based on clinical features of intrahepatic cholangiocarcinoma: the Fudan score. Ann Oncol. 2011;22(7):1644–1652. doi:10.1093/annonc/mdq650
   PubMed Web of Science ®Google Scholar
• Ribero D, Pinna AD, Guglielmi A, et al. Surgical approach for long-term survival of patients with intrahepatic cholangiocarcinoma: a multi-institutional analysis of 434 patients. Arch Surg. 2012;147(12):1107–1113. doi:10.1001/archsurg.2012.1962
   PubMedGoogle Scholar
• Valle J, Wasan H, Palmer DH, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010;362(14):1273–1281. doi:10.1056/NEJMoa0908721
   PubMed Web of Science ®Google Scholar
• Knox JJ, Hedley D, Oza A, et al. Combining gemcitabine and capecitabine in patients with advanced biliary cancer: a phase II trial. J Clin Oncol. 2005;23(10):2332–2338. doi:10.1200/JCO.2005.51.008
   PubMed Web of Science ®Google Scholar
• André T, Tournigand C, Rosmorduc O, et al. Gemcitabine combined with oxaliplatin (GEMOX) in advanced biliary tract adenocarcinoma: a GERCOR study. Ann Oncol. 2004;15(9):1339–1343. doi:10.1093/annonc/mdh351
   PubMed Web of Science ®Google Scholar
• Morizane C, Okusaka T, Mizusawa J, et al. Randomized phase II study of gemcitabine plus S-1 versus S-1 in advanced biliary tract cancer: a Japan Clinical Oncology Group trial (JCOG 0805). Cancer Sci. 2013;104(9):1211–1216. doi:10.1111/cas.12218
   PubMed Web of Science ®Google Scholar
• Mizusawa J, Morizane C, Okusaka T, et al. Randomized Phase III study of gemcitabine plus S-1 versus gemcitabine plus cisplatin in advanced biliary tract cancer: japan Clinical Oncology Group Study (JCOG1113, FUGA-BT). Jpn J Clin Oncol. 2016;46(4):385–388. doi:10.1093/jjco/hyv213
   PubMed Web of Science ®Google Scholar
• Morizane C, Okusaka T, Mizusawa J, et al. Combination gemcitabine plus S-1 versus gemcitabine plus cisplatin for advanced/recurrent biliary tract cancer: the FUGA-BT (JCOG1113) randomized phase III clinical trial. Ann Oncol. 2019;30(12):1950–1958. doi:10.1093/annonc/mdz402
   PubMed Web of Science ®Google Scholar
• Shroff RT, Javle MM, Xiao L, et al. Gemcitabine, cisplatin, and nab-paclitaxel for the treatment of advanced biliary tract cancers: a Phase 2 clinical trial. JAMA Oncol. 2019;5(6):824–830. doi:10.1001/jamaoncol.2019.0270
   PubMed Web of Science ®Google Scholar
• Lamarca A, Hubner RA, David Ryder W, Valle JW. Second-line chemotherapy in advanced biliary cancer: a systematic review. Ann Oncol. 2014;25(12):2328–2338. doi:10.1093/annonc/mdu162
   PubMed Web of Science ®Google Scholar
• Zheng Y, Tu X, Zhao P, et al. A randomised phase II study of second-line XELIRI regimen versus irinotecan monotherapy in advanced biliary tract cancer patients progressed on gemcitabine and cisplatin. Br J Cancer. 2018;119(3):291–295. doi:10.1038/s41416-018-0138-2
   PubMed Web of Science ®Google Scholar
• Martinez FJ, Shroff RT. Biliary tract cancers: systemic therapy for advanced disease. Chin Clin Oncol. 2020;9(1):5. doi:10.21037/cco.2019.12.07
   PubMed Web of Science ®Google Scholar
• Javle M, Bekaii-Saab T, Jain A, et al. Biliary cancer: utility of next-generation sequencing for clinical management. Cancer. 2016;122(24):3838–3847. doi:10.1002/cncr.30254
   PubMed Web of Science ®Google Scholar
• Lee H, Ross JS. The potential role of comprehensive genomic profiling to guide targeted therapy for patients with biliary cancer. Therap Adv Gastroenterol. 2017;10(6):507–520. doi:10.1177/1756283X17698090
   PubMed Web of Science ®Google Scholar
• Jain A, Javle M. Molecular profiling of biliary tract cancer: a target rich disease. J Gastrointest Oncol. 2016;7(5):797–803. doi:10.21037/jgo.2016.09.01
   PubMed Web of Science ®Google Scholar
• Nakamura H, Arai Y, Totoki Y, et al. Genomic spectra of biliary tract cancer. Nat Genet. 2015;47(9):1003–1010. doi:10.1038/ng.3375
   PubMed Web of Science ®Google Scholar
• Churi CR, Shroff R, Wang Y, et al. Mutation profiling in cholangiocarcinoma: prognostic and therapeutic implications. PLoS One. 2014;9(12):e115383. doi:10.1371/journal.pone.0115383
   PubMed Web of Science ®Google Scholar
• Krook MA, Lenyo A, Wilberding M, et al. Efficacy of FGFR inhibitors and combination therapies for acquired resistance in FGFR2-fusion cholangiocarcinoma. Mol Cancer Ther. 2020;19(3):847–857. doi:10.1158/1535-7163.MCT-19-0631
   PubMed Web of Science ®Google Scholar
• Dai S, Zhou Z, Chen Z, Xu G, Chen Y. Fibroblast growth factor receptors (FGFRs): structures and small molecule inhibitors. Cells. 2019;8(6):614. doi:10.3390/cells8060614
   PubMed Web of Science ®Google Scholar
• Itoh N, Ornitz DM. Evolution of the Fgf and Fgfr gene families. Trends Genet. 2004;20(11):563–569. doi:10.1016/j.tig.2004.08.007
   PubMed Web of Science ®Google Scholar
• Farrell B, Breeze AL. Structure, activation and dysregulation of fibroblast growth factor receptor kinases: perspectives for clinical targeting. Biochem Soc Trans. 2018;46(6):1753–1770. doi:10.1042/BST20180004
   PubMed Web of Science ®Google Scholar
• Coutts JC, Gallagher JT. Receptors for fibroblast growth factors. Immunol Cell Biol. 1995;73(6):584–589. doi:10.1038/icb.1995.92
   PubMed Web of Science ®Google Scholar
• Belov AA, Mohammadi M. Molecular mechanisms of fibroblast growth factor signaling in physiology and pathology. Cold Spring Harb Perspect Biol. 2013;5(6). doi:10.1101/cshperspect.a015958
   PubMed Web of Science ®Google Scholar
• Ornitz DM, Itoh N. The fibroblast growth factor signaling pathway. Wiley Interdiscip Rev Dev Biol. 2015;4(3):215–266.
   PubMed Web of Science ®Google Scholar
• Beenken A, Mohammadi M. The FGF family: biology, pathophysiology and therapy. Nat Rev Drug Discov. 2009;8(3):235–253.
   PubMed Web of Science ®Google Scholar
• Graham RP, Barr Fritcher EG, Pestova E, et al. Fibroblast growth factor receptor 2 translocations in intrahepatic cholangiocarcinoma. Hum Pathol. 2014;45(8):1630–1638. doi:10.1016/j.humpath.2014.03.014
   PubMed Web of Science ®Google Scholar
• Mertens JC, Rizvi S, Gores GJ. Targeting cholangiocarcinoma. Biochim Biophys Acta Mol Basis Dis. 2018;1864(4 Pt B):1454–1460. doi:10.1016/j.bbadis.2017.08.027
   PubMed Web of Science ®Google Scholar
• Wu YM, Su F, Kalyana-Sundaram S, et al. Identification of targetable FGFR gene fusions in diverse cancers. Cancer Discov. 2013;3(6):636–647. doi:10.1158/2159-8290.CD-13-0050
   PubMed Web of Science ®Google Scholar
• Arai Y, Totoki Y, Hosoda F, et al. Fibroblast growth factor receptor 2 tyrosine kinase fusions define a unique molecular subtype of cholangiocarcinoma. Hepatology. 2014;59(4):1427–1434. doi:10.1002/hep.26890
   PubMed Web of Science ®Google Scholar
• Chong DQ, Zhu AX. The landscape of targeted therapies for cholangiocarcinoma: current status and emerging targets. Oncotarget. 2016;7(29):46750–46767. doi:10.18632/oncotarget.8775
   PubMedGoogle Scholar
• Ghedini GC, Ronca R, Presta M, Giacomini A. Future applications of FGF/FGFR inhibitors in cancer. Expert Rev Anticancer Ther. 2018;18(9):861–872. doi:10.1080/14737140.2018.1491795
   PubMed Web of Science ®Google Scholar
• Guagnano V, Kauffmann A, Wohrle S, et al. FGFR genetic alterations predict for sensitivity to NVP-BGJ398, a selective pan-FGFR inhibitor. Cancer Discov. 2012;2(12):1118–1133. doi:10.1158/2159-8290.CD-12-0210
   PubMed Web of Science ®Google Scholar
• Guagnano V, Furet P, Spanka C, et al. Discovery of 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), a potent and selective inhibitor of the fibroblast growth factor receptor family of receptor tyrosine kinase. J Med Chem. 2011;54(20):7066–7083. doi:10.1021/jm2006222
   PubMed Web of Science ®Google Scholar
• Javle M, Lowery M, Shroff RT, et al. Phase II Study of BGJ398 in patients with FGFR-altered advanced cholangiocarcinoma. J Clin Oncol. 2018;36(3):276–282. doi:10.1200/JCO.2017.75.5009
   PubMed Web of Science ®Google Scholar
• Gilbert JA. BGJ398 for FGFR-altered advanced cholangiocarcinoma. Lancet Oncol. 2018;19(1):e16. doi:10.1016/S1470-2045(17)30902-6
   PubMed Web of Science ®Google Scholar
• Chila R, Hall GT, Abbadessa G, Broggini M, Damia G. Multi-chemotherapeutic schedules containing the pan-FGFR inhibitor ARQ 087 are safe and show antitumor activity in different xenograft models. Transl Oncol. 2017;10(2):153–157. doi:10.1016/j.tranon.2016.12.003
   PubMed Web of Science ®Google Scholar
• Papadopoulos KP, El-Rayes BF, Tolcher AW, et al. A Phase 1 study of ARQ 087, an oral pan-FGFR inhibitor in patients with advanced solid tumours. Br J Cancer. 2017;117(11):1592–1599. doi:10.1038/bjc.2017.330
   PubMed Web of Science ®Google Scholar
• Hall TG, Yu Y, Eathiraj S, et al. Preclinical activity of ARQ 087, a novel inhibitor targeting FGFR dysregulation. PLoS One. 2016;11(9):e0162594. doi:10.1371/journal.pone.0162594
   PubMed Web of Science ®Google Scholar
• Raggi C, Fiaccadori K, Pastore M, et al. Antitumor activity of a novel fibroblast growth factor receptor inhibitor for intrahepatic cholangiocarcinoma. Am J Pathol. 2019;189(10):2090–2101. doi:10.1016/j.ajpath.2019.06.007
   PubMed Web of Science ®Google Scholar
• Mazzaferro V, El-Rayes BF, Droz Dit Busset M, et al. Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma. Br J Cancer. 2019;120(2):165–171. doi:10.1038/s41416-018-0334-0
   PubMed Web of Science ®Google Scholar
• Kalyukina M, Yosaatmadja Y, Middleditch MJ, Patterson AV, Smaill JB, Squire CJ. TAS-120 cancer target binding: defining reactivity and revealing the first fibroblast growth factor receptor 1 (FGFR1) irreversible structure. ChemMedChem. 2019;14(4):494–500. doi:10.1002/cmdc.201800719
   PubMed Web of Science ®Google Scholar
• Goyal L, Shi L, Liu LY, et al. TAS-120 overcomes resistance to ATP-competitive FGFR inhibitors in patients with FGFR2 fusion-positive intrahepatic cholangiocarcinoma. Cancer Discov. 2019;9(8):1064–1079. doi:10.1158/2159-8290.CD-19-0182
   PubMed Web of Science ®Google Scholar
• Bahleda R, Meric-Bernstam F, Goyal L, et al. Phase I, first-in-human study of futibatinib, a highly selective, irreversible FGFR1-4 inhibitor in patients with advanced solid tumors. Ann Oncol. 2020;31(10):1405–1412. doi:10.1016/j.annonc.2020.06.018
   PubMed Web of Science ®Google Scholar
• Rizzo A, Ricci AD, Brandi G. Futibatinib, an investigational agent for the treatment of intrahepatic cholangiocarcinoma: evidence to date and future perspectives. Expert Opin Investig Drugs. 2020:1–8.
   Web of Science ®Google Scholar
• Roskoski R Jr. The role of fibroblast growth factor receptor (FGFR) protein-tyrosine kinase inhibitors in the treatment of cancers including those of the urinary bladder. Pharmacol Res. 2020;151:104567. doi:10.1016/j.phrs.2019.104567
   PubMed Web of Science ®Google Scholar
• Krook MA, Bonneville R, Chen HZ, et al. Tumor heterogeneity and acquired drug resistance in FGFR2-fusion-positive cholangiocarcinoma through rapid research autopsy. Cold Spring Harb Mol Case Stud. 2019;5(4):a004002. doi:10.1101/mcs.a004002
   PubMed Web of Science ®Google Scholar
• Abou-Alfa GK, Sahai V, Hollebecque A, et al. Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study. Lancet Oncol. 2020;21(5):671–684. doi:10.1016/S1470-2045(20)30109-1
   PubMed Web of Science ®Google Scholar
• Harris PA, Boloor A, Cheung M, et al. Discovery of 5-[[4-[(2,3-dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methyl-b enzenesulfonamide (Pazopanib), a novel and potent vascular endothelial growth factor receptor inhibitor. J Med Chem. 2008;51(15):4632–4640. doi:10.1021/jm800566m
   PubMed Web of Science ®Google Scholar
• Kim ST, Jang HL, Lee SJ, et al. Pazopanib, a novel multitargeted kinase inhibitor, shows potent in vitro antitumor activity in gastric cancer cell lines with FGFR2 amplification. Mol Cancer Ther. 2014;13(11):2527–2536. doi:10.1158/1535-7163.MCT-14-0255
   PubMed Web of Science ®Google Scholar
• Sgouros J, Aravantinos G, Koliou GA, et al. First line gemcitabine/pazopanib in locally advanced and/or metastatic biliary tract carcinoma. A Hellenic Cooperative Oncology Group Phase II Study. Anticancer Res. 2020;40(2):929–938. doi:10.21873/anticanres.14026
   PubMed Web of Science ®Google Scholar
• Tan FH, Putoczki TL, Stylli SS, Luwor RB. Ponatinib: a novel multi-tyrosine kinase inhibitor against human malignancies. Onco Targets Ther. 2019;12:635–645. doi:10.2147/OTT.S189391
   PubMed Web of Science ®Google Scholar
• Borad MJ, Champion MD, Egan JB, et al. Integrated genomic characterization reveals novel, therapeutically relevant drug targets in FGFR and EGFR pathways in sporadic intrahepatic cholangiocarcinoma. PLoS Genet. 2014;10(2):e1004135. doi:10.1371/journal.pgen.1004135
   PubMed Web of Science ®Google Scholar
• Nicolini FE, Gagnieu M-C, Heiblig M, et al. Cardio-vascular events occurring on ponatinib in chronic phase chronic myeloid leukemia patients, preliminary analysis of a multicenter cohort. Blood. 2013;122(21):4020. doi:10.1182/blood.V122.21.4020.4020
   Google Scholar
• Catenacci DVT, Rasco D, Lee J, et al. Phase I escalation and expansion study of bemarituzumab (FPA144) in patients with advanced solid tumors and FGFR2b-selected gastroesophageal adenocarcinoma. J Clin Oncol. 2020;38(21):Jco1901834. doi:10.1200/JCO.19.01834
   Web of Science ®Google Scholar
• Tabernero J, Bahleda R, Dienstmann R, et al. Phase I dose-escalation study of JNJ-42756493, an oral pan-fibroblast growth factor receptor inhibitor, in patients with advanced solid tumors. J Clin Oncol. 2015;33(30):3401–3408. doi:10.1200/JCO.2014.60.7341
   PubMed Web of Science ®Google Scholar
• Bahleda R, Italiano A, Hierro C, et al. Multicenter Phase I study of erdafitinib (JNJ-42756493), oral pan-fibroblast growth factor receptor inhibitor, in patients with advanced or refractory solid tumors. Clin Cancer Res. 2019;25(16):4888–4897. doi:10.1158/1078-0432.CCR-18-3334
   PubMed Web of Science ®Google Scholar
• Goyal L, Saha SK, Liu LY, et al. Polyclonal secondary FGFR2 mutations drive acquired resistance to FGFR inhibition in patients with FGFR2 fusion-positive cholangiocarcinoma. Cancer Discov. 2017;7(3):252–263. doi:10.1158/2159-8290.CD-16-1000
   PubMed Web of Science ®Google Scholar
• Byron SA, Chen H, Wortmann A, et al. The N550K/H mutations in FGFR2 confer differential resistance to PD173074, dovitinib, and ponatinib ATP-competitive inhibitors. Neoplasia. 2013;15(8):975–988. doi:10.1593/neo.121106
   PubMed Web of Science ®Google Scholar
• Kim SY, Ahn T, Bang H, et al. Acquired resistance to LY2874455 in FGFR2-amplified gastric cancer through an emergence of novel FGFR2-ACSL5 fusion. Oncotarget. 2017;8(9):15014–15022. doi:10.18632/oncotarget.14788
   PubMedGoogle Scholar
• Dalziel K. Isocitrate dehydrogenase and related oxidative decarboxylases. FEBS Lett. 1980;117(Suppl):K45–K55. doi:10.1016/0014-5793(80)80569-2
   PubMedGoogle Scholar
• Kipp BR, Voss JS, Kerr SE, et al. Isocitrate dehydrogenase 1 and 2 mutations in cholangiocarcinoma. Hum Pathol. 2012;43(10):1552–1558. doi:10.1016/j.humpath.2011.12.007
   PubMed Web of Science ®Google Scholar
• Dang L, White DW, Gross S, et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature. 2009;462(7274):739–744. doi:10.1038/nature08617
   PubMed Web of Science ®Google Scholar
• Lu C, Ward PS, Kapoor GS, et al. IDH mutation impairs histone demethylation and results in a block to cell differentiation. Nature. 2012;483(7390):474–478. doi:10.1038/nature10860
   PubMed Web of Science ®Google Scholar
• Chowdhury R, Yeoh KK, Tian YM, et al. The oncometabolite 2-hydroxyglutarate inhibits histone lysine demethylases. EMBO Rep. 2011;12(5):463–469. doi:10.1038/embor.2011.43
   PubMed Web of Science ®Google Scholar
• Evans B, Griner E. Registered report: oncometabolite 2-hydroxyglutarate is a competitive inhibitor of alpha-ketoglutarate-dependent dioxygenases. Elife. 2015;4:e07420. doi:10.7554/eLife.07420
   PubMed Web of Science ®Google Scholar
• Wang F, Travins J, DeLaBarre B, et al. Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiation. Science. 2013;340(6132):622–626. doi:10.1126/science.1234769
   PubMed Web of Science ®Google Scholar
• Turcan S, Rohle D, Goenka A, et al. IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype. Nature. 2012;483(7390):479–483. doi:10.1038/nature10866
   PubMed Web of Science ®Google Scholar
• Wang P, Dong Q, Zhang C, et al. Mutations in isocitrate dehydrogenase 1 and 2 occur frequently in intrahepatic cholangiocarcinomas and share hypermethylation targets with glioblastomas. Oncogene. 2013;32(25):3091–3100. doi:10.1038/onc.2012.315
   PubMed Web of Science ®Google Scholar
• Farshidfar F, Zheng S, Gingras MC, et al. Integrative genomic analysis of cholangiocarcinoma identifies distinct IDH-mutant molecular profiles. Cell Rep. 2017;19(13):2878–2880. doi:10.1016/j.celrep.2017.06.008
   PubMed Web of Science ®Google Scholar
• Ross JS, Wang K, Gay L, et al. New routes to targeted therapy of intrahepatic cholangiocarcinomas revealed by next-generation sequencing. Oncologist. 2014;19(3):235–242. doi:10.1634/theoncologist.2013-0352
   PubMed Web of Science ®Google Scholar
• Borger DR, Tanabe KK, Fan KC, et al. Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping. Oncologist. 2012;17(1):72–79. doi:10.1634/theoncologist.2011-0386
   PubMed Web of Science ®Google Scholar
• Rohle D, Popovici-Muller J, Palaskas N, et al. An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells. Science. 2013;340(6132):626–630. doi:10.1126/science.1236062
   PubMed Web of Science ®Google Scholar
• Popovici-Muller J, Lemieux RM, Artin E, et al. Discovery of AG-120 (Ivosidenib): a first-in-class mutant IDH1 inhibitor for the treatment of IDH1 mutant cancers. ACS Med Chem Lett. 2018;9(4):300–305. doi:10.1021/acsmedchemlett.7b00421
   PubMed Web of Science ®Google Scholar
• Golub D, Iyengar N, Dogra S, et al. Mutant isocitrate dehydrogenase inhibitors as targeted cancer therapeutics. Front Oncol. 2019;9:417. doi:10.3389/fonc.2019.00417
   PubMed Web of Science ®Google Scholar
• Hansen E, Quivoron C, Straley K, et al. AG-120, an oral, selective, first-in-class, potent inhibitor of mutant IDH1, reduces intracellular 2HG and induces cellular differentiation in TF-1 R132H cells and primary human IDH1 mutant AML patient samples treated ex vivo. Blood. 2014;124(21):3734. doi:10.1182/blood.V124.21.3734.3734
   Web of Science ®Google Scholar
• Lowery MA, Burris HA 3rd, Janku F, et al. Safety and activity of ivosidenib in patients with IDH1-mutant advanced cholangiocarcinoma: a phase 1 study. Lancet Gastroenterol Hepatol. 2019;4(9):711–720. doi:10.1016/S2468-1253(19)30189-X
   PubMed Web of Science ®Google Scholar
• Ishii Y, Sigel C, Lowery MA, et al. editor AG-120 (ivosidenib), a first-in-class mutant IDH1 inhibitor, promotes morphologic changes and upregulates liver-specific genes in IDH1 mutant cholangiocarcinoma. AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics; 2017; Philadelphia, PA, USA.
   Google Scholar
• Ghassan K, Abou-Alfa TM, Javle M, editor ClarIDHy: a global, phase 3, randomized, double-blind study of ivosidenib vs placebo in patients with advanced cholangiocarcinoma with an isocitrate dehydrogenase 1 (IDH1) mutation; 2019.
   Google Scholar
• Caravella JA, Lin J, Diebold RB, et al. Structure-based design and identification of FT-2102 (Olutasidenib), a potent mutant-selective IDH1 inhibitor. J Med Chem. 2020;63(4):1612–1623. doi:10.1021/acs.jmedchem.9b01423
   PubMed Web of Science ®Google Scholar
• Cho YS, Levell JR, Liu G, et al. Discovery and evaluation of clinical candidate IDH305, a brain penetrant mutant IDH1 inhibitor. ACS Med Chem Lett. 2017;8(10):1116–1121. doi:10.1021/acsmedchemlett.7b00342
   PubMed Web of Science ®Google Scholar
• DiNardo CD, Schimmer AD, Yee KWL, et al. A Phase I Study of IDH305 in patients with advanced malignancies including relapsed/refractory AML and MDS that harbor IDH1R132 mutations. Blood. 2016;128(22):1073. doi:10.1182/blood.V128.22.1073.1073
   Web of Science ®Google Scholar
• Yen K, Travins J, Wang F, et al. AG-221, a first-in-class therapy targeting acute myeloid leukemia harboring oncogenic IDH2 mutations. Cancer Discov. 2017;7(5):478–493. doi:10.1158/2159-8290.CD-16-1034
   PubMed Web of Science ®Google Scholar
• Chen J, Yang J, Cao P. The evolving landscape in the development of isocitrate dehydrogenase mutant inhibitors. Mini Rev Med Chem. 2016;16(16):1344–1358. doi:10.2174/1389557516666160609085520
   PubMed Web of Science ®Google Scholar
• Ma R, Yun CH. Crystal structures of pan-IDH inhibitor AG-881 in complex with mutant human IDH1 and IDH2. Biochem Biophys Res Commun. 2018;503(4):2912–2917. doi:10.1016/j.bbrc.2018.08.068
   PubMed Web of Science ®Google Scholar
• Saha SK, Gordan JD, Kleinstiver BP, et al. Isocitrate dehydrogenase mutations confer dasatinib hypersensitivity and SRC dependence in intrahepatic cholangiocarcinoma. Cancer Discov. 2016;6(7):727–739. doi:10.1158/2159-8290.CD-15-1442
   PubMed Web of Science ®Google Scholar
• Sulkowski PL, Corso CD, Robinson ND, et al. 2-Hydroxyglutarate produced by neomorphic IDH mutations suppresses homologous recombination and induces PARP inhibitor sensitivity. Sci Transl Med. 2017;9:375. doi:10.1126/scitranslmed.aal2463
   Web of Science ®Google Scholar
• Molenaar RJ, Radivoyevitch T, Nagata Y, et al. IDH1/2 mutations sensitize acute myeloid leukemia to PARP inhibition and this is reversed by IDH1/2-mutant inhibitors. Clin Cancer Res. 2018;24(7):1705–1715. doi:10.1158/1078-0432.CCR-17-2796
   PubMed Web of Science ®Google Scholar
• Spizzo G, Puccini A, Xiu J, et al. Molecular profile of BRCA-mutated biliary tract cancers. ESMO Open. 2020;5(3):e000682. doi:10.1136/esmoopen-2020-000682
   PubMed Web of Science ®Google Scholar
• Hynes NE, Lane HA. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer. 2005;5(5):341–354. doi:10.1038/nrc1609
   PubMed Web of Science ®Google Scholar
• Sirica AE. Role of ErbB family receptor tyrosine kinases in intrahepatic cholangiocarcinoma. World J Gastroenterol. 2008;14(46):7033–7058. doi:10.3748/wjg.14.7033
   PubMed Web of Science ®Google Scholar
• Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol. 2001;2(2):127–137. doi:10.1038/35052073
   PubMed Web of Science ®Google Scholar
• Olayioye MA, Neve RM, Lane HA, Hynes NE. The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO j. 2000;19(13):3159–3167. doi:10.1093/emboj/19.13.3159
   PubMed Web of Science ®Google Scholar
• Oda K, Matsuoka Y, Funahashi A, Kitano H. A comprehensive pathway map of epidermal growth factor receptor signaling. Mol Syst Biol. 2005;1:2005.0010. doi:10.1038/msb4100014
   PubMed Web of Science ®Google Scholar
• Sunpaweravong P, Sunpaweravong S, Puttawibul P, et al. Epidermal growth factor receptor and cyclin D1 are independently amplified and overexpressed in esophageal squamous cell carcinoma. J Cancer Res Clin Oncol. 2005;131(2):111–119. doi:10.1007/s00432-004-0610-7
   PubMed Web of Science ®Google Scholar
• Salomon DS, Brandt R, Ciardiello F, Normanno N. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol. 1995;19(3):183–232.
   PubMed Web of Science ®Google Scholar
• Pignochino Y, Sarotto I, Peraldo-Neia C, et al. Targeting EGFR/HER2 pathways enhances the antiproliferative effect of gemcitabine in biliary tract and gallbladder carcinomas. BMC Cancer. 2010;10:631. doi:10.1186/1471-2407-10-631
   PubMed Web of Science ®Google Scholar
• Nakazawa K, Dobashi Y, Suzuki S, Fujii H, Takeda Y, Ooi A. Amplification and overexpression of c-erbB-2, epidermal growth factor receptor, and c-met in biliary tract cancers. J Pathol. 2005;206(3):356–365. doi:10.1002/path.1779
   PubMed Web of Science ®Google Scholar
• Yoshikawa D, Ojima H, Iwasaki M, et al. Clinicopathological and prognostic significance of EGFR, VEGF, and HER2 expression in cholangiocarcinoma. Br J Cancer. 2008;98(2):418–425. doi:10.1038/sj.bjc.6604129
   PubMed Web of Science ®Google Scholar
• Leone F, Cavalloni G, Pignochino Y, et al. Somatic mutations of epidermal growth factor receptor in bile duct and gallbladder carcinoma. Clin Cancer Res. 2006;12(6):1680–1685. doi:10.1158/1078-0432.CCR-05-1692
   PubMed Web of Science ®Google Scholar
• Wiedmann M, Feisthammel J, Blüthner T, et al. Novel targeted approaches to treating biliary tract cancer: the dual epidermal growth factor receptor and ErbB-2 tyrosine kinase inhibitor NVP-AEE788 is more efficient than the epidermal growth factor receptor inhibitors gefitinib and erlotinib. Anticancer Drugs. 2006;17(7):783–795. doi:10.1097/01.cad.0000217433.48870.37
   PubMed Web of Science ®Google Scholar
• Kiguchi K, Ruffino L, Kawamoto T, Ajiki T, Digiovanni J. Chemopreventive and therapeutic efficacy of orally active tyrosine kinase inhibitors in a transgenic mouse model of gallbladder carcinoma. Clin Cancer Res. 2005;11(15):5572–5580. doi:10.1158/1078-0432.CCR-04-2603
   PubMed Web of Science ®Google Scholar
• Philip PA, Mahoney MR, Allmer C, et al. Phase II study of erlotinib in patients with advanced biliary cancer. J Clin Oncol. 2006;24(19):3069–3074. doi:10.1200/JCO.2005.05.3579
   PubMed Web of Science ®Google Scholar
• Lee J, Park SH, Chang HM, et al. Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer: a multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 2012;13(2):181–188. doi:10.1016/S1470-2045(11)70301-1
   PubMed Web of Science ®Google Scholar
• Gruenberger B, Schueller J, Heubrandtner U, et al. Cetuximab, gemcitabine, and oxaliplatin in patients with unresectable advanced or metastatic biliary tract cancer: a phase 2 study. Lancet Oncol. 2010;11(12):1142–1148. doi:10.1016/S1470-2045(10)70247-3
   PubMed Web of Science ®Google Scholar
• Malka D, Cervera P, Foulon S, et al. Gemcitabine and oxaliplatin with or without cetuximab in advanced biliary-tract cancer (BINGO): a randomised, open-label, non-comparative phase 2 trial. Lancet Oncol. 2014;15(8):819–828. doi:10.1016/S1470-2045(14)70212-8
   PubMed Web of Science ®Google Scholar
• Van Cutsem E, Köhne CH, Hitre E, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med. 2009;360(14):1408–1417. doi:10.1056/NEJMoa0805019
   PubMed Web of Science ®Google Scholar
• Chen JS, Hsu C, Chiang NJ, et al. A KRAS mutation status-stratified randomized phase II trial of gemcitabine and oxaliplatin alone or in combination with cetuximab in advanced biliary tract cancer. Ann Oncol. 2015;26(5):943–949. doi:10.1093/annonc/mdv035
   PubMed Web of Science ®Google Scholar
• Leone F, Marino D, Cereda S, et al. Panitumumab in combination with gemcitabine and oxaliplatin does not prolong survival in wild-type KRAS advanced biliary tract cancer: a randomized phase 2 trial (Vecti-BIL study). Cancer. 2016;122(4):574–581. doi:10.1002/cncr.29778
   PubMed Web of Science ®Google Scholar
• Vogel A, Kasper S, Bitzer M, et al. PICCA study: panitumumab in combination with cisplatin/gemcitabine chemotherapy in KRAS wild-type patients with biliary cancer-a randomised biomarker-driven clinical phase II AIO study. Eur J Cancer. 2018;92:11–19. doi:10.1016/j.ejca.2017.12.028
   PubMed Web of Science ®Google Scholar
• Yamashita-Kashima Y, Yoshimura Y, Fujimura T, et al. Molecular targeting of HER2-overexpressing biliary tract cancer cells with trastuzumab emtansine, an antibody-cytotoxic drug conjugate. Cancer Chemother Pharmacol. 2019;83(4):659–671. doi:10.1007/s00280-019-03768-8
   PubMed Web of Science ®Google Scholar
• Nam AR, Kim JW, Cha Y, et al. Therapeutic implication of HER2 in advanced biliary tract cancer. Oncotarget. 2016;7(36):58007–58021. doi:10.18632/oncotarget.11157
   PubMedGoogle Scholar
• Javle M, Churi C, Kang HC, et al. HER2/neu-directed therapy for biliary tract cancer. J Hematol Oncol. 2015;8:58. doi:10.1186/s13045-015-0155-z
   PubMed Web of Science ®Google Scholar
• Kawamoto T, Ishige K, Thomas M, et al. Overexpression and gene amplification of EGFR, HER2, and HER3 in biliary tract carcinomas, and the possibility for therapy with the HER2-targeting antibody pertuzumab. J Gastroenterol. 2015;50(4):467–479. doi:10.1007/s00535-014-0984-5
   PubMed Web of Science ®Google Scholar
• Yarlagadda B, Kamatham V, Ritter A, Shahjehan F, Kasi PM. Trastuzumab and pertuzumab in circulating tumor DNA ERBB2-amplified HER2-positive refractory cholangiocarcinoma. NPJ Precis Oncol. 2019;3:19. doi:10.1038/s41698-019-0091-4
   PubMed Web of Science ®Google Scholar
• Czink E, Heining C, Weber TF, et al. [Durable remission under dual HER2 blockade with Trastuzumab and Pertuzumab in a patient with metastatic gallbladder cancer]. Z Gastroenterol. 2016;54(5):426–430. doi:10.1055/s-0042-103498
   PubMed Web of Science ®Google Scholar
• Ramanathan RK, Belani CP, Singh DA, et al. A phase II study of lapatinib in patients with advanced biliary tree and hepatocellular cancer. Cancer Chemother Pharmacol. 2009;64(4):777–783. doi:10.1007/s00280-009-0927-7
   PubMed Web of Science ®Google Scholar
• Peck J, Wei L, Zalupski M, O’Neil B, Villalona Calero M, Bekaii-Saab T. HER2/neu may not be an interesting target in biliary cancers: results of an early phase II study with lapatinib. Oncology. 2012;82(3):175–179. doi:10.1159/000336488
   PubMed Web of Science ®Google Scholar
• Moehler M, Maderer A, Ehrlich A, et al. Safety and efficacy of afatinib as add-on to standard therapy of gemcitabine/cisplatin in chemotherapy-naive patients with advanced biliary tract cancer: an open-label, phase I trial with an extensive biomarker program. BMC Cancer. 2019;19(1):55. doi:10.1186/s12885-018-5223-7
   PubMedGoogle Scholar
• Profiling differential responses to Pan-HER inhibition. Cancer Discov. 2017;7(6):Of12. doi:10.1158/2159-8290.CD-NB2017-052
   PubMedGoogle Scholar
• Dokduang H, Jamnongkarn W, Promraksa B, et al. In vitro and in vivo anti-tumor effects of Pan-HER inhibitor varlitinib on cholangiocarcinoma cell lines. Drug Des Devel Ther. 2020;14:2319–2334. doi:10.2147/DDDT.S250061
   PubMed Web of Science ®Google Scholar
• Nam HJ, Kim HP, Yoon YK, et al. The irreversible pan-HER inhibitor PF00299804 alone or combined with gemcitabine has an antitumor effect in biliary tract cancer cell lines. Invest New Drugs. 2012;30(6):2148–2160. doi:10.1007/s10637-011-9782-6
   PubMed Web of Science ®Google Scholar
• Skaper SD. The biology of neurotrophins, signalling pathways, and functional peptide mimetics of neurotrophins and their receptors. CNS Neurol Disord Drug Targets. 2008;7(1):46–62. doi:10.2174/187152708783885174
   PubMed Web of Science ®Google Scholar
• Cocco E, Scaltriti M, Drilon A. NTRK fusion-positive cancers and TRK inhibitor therapy. Nat Rev Clin Oncol. 2018;15(12):731–747. doi:10.1038/s41571-018-0113-0
   PubMed Web of Science ®Google Scholar
• Reichardt LF. Neurotrophin-regulated signalling pathways. Philos Trans R Soc Lond B Biol Sci. 2006;361(1473):1545–1564. doi:10.1098/rstb.2006.1894
   PubMed Web of Science ®Google Scholar
• Nakagawara A. Trk receptor tyrosine kinases: a bridge between cancer and neural development. Cancer Lett. 2001;169(2):107–114. doi:10.1016/S0304-3835(01)00530-4
   PubMed Web of Science ®Google Scholar
• Solomon JP, Linkov I, Rosado A, et al. NTRK fusion detection across multiple assays and 33,997 cases: diagnostic implications and pitfalls. Mod Pathol. 2020;33(1):38–46. doi:10.1038/s41379-019-0324-7
   PubMed Web of Science ®Google Scholar
• Demols A, Perez-Casanova L, Rocq L, et al. 71P NTRK gene fusions in bilio-pancreatic cancers. Ann Oncol. 2020;31:233. doi:10.1016/j.annonc.2020.04.057
   Google Scholar
• Lamarca A, Barriuso J, McNamara MG, Valle JW. Molecular targeted therapies: ready for “prime time” in biliary tract cancer. J Hepatol. 2020;73(1):170–185. doi:10.1016/j.jhep.2020.03.007
   PubMed Web of Science ®Google Scholar
• Eguchi M, Eguchi-Ishimae M, Tojo A, et al. Fusion of ETV6 to neurotrophin-3 receptor TRKC in acute myeloid leukemia with t(12;15)(p13;q25). Blood. 1999;93(4):1355–1363. doi:10.1182/blood.V93.4.1355
   PubMed Web of Science ®Google Scholar
• Cook PJ, Thomas R, Kannan R, et al. Somatic chromosomal engineering identifies BCAN-NTRK1 as a potent glioma driver and therapeutic target. Nat Commun. 2017;8:15987. doi:10.1038/ncomms15987
   PubMed Web of Science ®Google Scholar
• Drilon A, Nagasubramanian R, Blake JF, et al. A next-generation TRK kinase inhibitor overcomes acquired resistance to prior TRK kinase inhibition in patients with TRK fusion-positive solid tumors. Cancer Discov. 2017;7(9):963–972. doi:10.1158/2159-8290.CD-17-0507
   PubMed Web of Science ®Google Scholar
• Amatu A, Sartore-Bianchi A, Bencardino K, Pizzutilo EG, Tosi F, Siena S. Tropomyosin receptor kinase (TRK) biology and the role of NTRK gene fusions in cancer. Ann Oncol. 2019;30(Suppl 8):viii5–viii15. doi:10.1093/annonc/mdz383
   PubMedGoogle Scholar
• Rolfo C, Ruiz R, Giovannetti E, et al. Entrectinib: a potent new TRK, ROS1, and ALK inhibitor. Expert Opin Investig Drugs. 2015;24(11):1493–1500. doi:10.1517/13543784.2015.1096344
   PubMed Web of Science ®Google Scholar
• Kawamoto M, Ozono K, Oyama Y, Yamasaki A, Oda Y, Onishi H. The novel selective pan-TRK inhibitor ONO-7579 exhibits antitumor efficacy against human gallbladder cancer in vitro. Anticancer Res. 2018;38(4):1979–1986. doi:10.21873/anticanres.12435
   PubMed Web of Science ®Google Scholar
• Karnoub AE, Weinberg RA. Ras oncogenes: split personalities. Nat Rev Mol Cell Biol. 2008;9(7):517–531.
   PubMed Web of Science ®Google Scholar
• Malumbres M, Barbacid M. RAS oncogenes: the first 30 years. Nat Rev Cancer. 2003;3(6):459–465. doi:10.1038/nrc1097
   PubMed Web of Science ®Google Scholar
• Brown MD, Sacks DB. Protein scaffolds in MAP kinase signalling. Cell Signal. 2009;21(4):462–469. doi:10.1016/j.cellsig.2008.11.013
   PubMed Web of Science ®Google Scholar
• Hazzalin CA, Mahadevan LC. MAPK-regulated transcription: a continuously variable gene switch? Nat Rev Mol Cell Biol. 2002;3(1):30–40. doi:10.1038/nrm715
   PubMed Web of Science ®Google Scholar
• Dhillon AS, Hagan S, Rath O, Kolch W. MAP kinase signalling pathways in cancer. Oncogene. 2007;26(22):3279–3290. doi:10.1038/sj.onc.1210421
   PubMed Web of Science ®Google Scholar
• Wellbrock C, Karasarides M, Marais R. The RAF proteins take centre stage. Nat Rev Mol Cell Biol. 2004;5(11):875–885. doi:10.1038/nrm1498
   PubMed Web of Science ®Google Scholar
• Walter D, Hartmann S, Waidmann O. Update on cholangiocarcinoma: potential impact of genomic studies on clinical management. Z Gastroenterol. 2017;55(6):575–581. doi:10.1055/s-0043-102581
   PubMed Web of Science ®Google Scholar
• Ohashi K, Tstsumi M, Nakajima Y, Nakano H, Konishi Y. Ki-ras point mutations and proliferation activity in biliary tract carcinomas. Br J Cancer. 1996;74(6):930–935. doi:10.1038/bjc.1996.459
   PubMed Web of Science ®Google Scholar
• Voss JS, Holtegaard LM, Kerr SE, et al. Molecular profiling of cholangiocarcinoma shows potential for targeted therapy treatment decisions. Hum Pathol. 2013;44(7):1216–1222. doi:10.1016/j.humpath.2012.11.006
   PubMed Web of Science ®Google Scholar
• Goeppert B, Frauenschuh L, Renner M, et al. BRAF V600E-specific immunohistochemistry reveals low mutation rates in biliary tract cancer and restriction to intrahepatic cholangiocarcinoma. Mod Pathol. 2014;27(7):1028–1034. doi:10.1038/modpathol.2013.206
   PubMed Web of Science ®Google Scholar
• Hyman DM, Puzanov I, Subbiah V, et al. Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutations. N Engl J Med. 2015;373(8):726–736. doi:10.1056/NEJMoa1502309
   PubMed Web of Science ®Google Scholar
• Silkin SV, Startsev SS, Krasnova ME, et al. Complete clinical response of BRAF-mutated cholangiocarcinoma to vemurafenib, panitumumab, and irinotecan. J Gastrointest Cancer. 2016;47(4):502–505. doi:10.1007/s12029-015-9792-2
   PubMedGoogle Scholar
• Loaiza-Bonilla A, Clayton E, Furth E, O’Hara M, Morrissette J. Dramatic response to dabrafenib and trametinib combination in a BRAF V600E-mutated cholangiocarcinoma: implementation of a molecular tumour board and next-generation sequencing for personalized medicine. Ecancermedicalscience. 2014;8:479. doi:10.3332/ecancer.2014.479
   PubMedGoogle Scholar
• Subbiah V, Lassen U, Élez E, et al. Dabrafenib plus trametinib in patients with BRAF(V600E)-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial. Lancet Oncol. 2020;21(9):1234–1243. doi:10.1016/S1470-2045(20)30321-1
   PubMed Web of Science ®Google Scholar
• Lee JK, Capanu M, O’Reilly EM, et al. A phase II study of gemcitabine and cisplatin plus sorafenib in patients with advanced biliary adenocarcinomas. Br J Cancer. 2013;109(4):915–919. doi:10.1038/bjc.2013.432
   PubMed Web of Science ®Google Scholar
• Bekaii-Saab T, Phelps MA, Li X, et al. Multi-institutional phase II study of selumetinib in patients with metastatic biliary cancers. J Clin Oncol. 2011;29(17):2357–2363. doi:10.1200/JCO.2010.33.9473
   PubMed Web of Science ®Google Scholar
• Bridgewater J, Lopes A, Beare S, et al. A phase 1b study of Selumetinib in combination with Cisplatin and Gemcitabine in advanced or metastatic biliary tract cancer: the ABC-04 study. BMC Cancer. 2016;16:153. doi:10.1186/s12885-016-2174-8
   PubMed Web of Science ®Google Scholar
• Ikeda M, Ioka T, Fukutomi A, et al. Efficacy and safety of trametinib in Japanese patients with advanced biliary tract cancers refractory to gemcitabine. Cancer Sci. 2018;109(1):215–224. doi:10.1111/cas.13438
   PubMed Web of Science ®Google Scholar
• Shroff RT, Yarchoan M, O’Connor A, et al. The oral VEGF receptor tyrosine kinase inhibitor pazopanib in combination with the MEK inhibitor trametinib in advanced cholangiocarcinoma. Br J Cancer. 2017;116(11):1402–1407. doi:10.1038/bjc.2017.119
   PubMed Web of Science ®Google Scholar
• Bendell JC, Javle M, Bekaii-Saab TS, et al. A phase 1 dose-escalation and expansion study of binimetinib (MEK162), a potent and selective oral MEK1/2 inhibitor. Br J Cancer. 2017;116(5):575–583. doi:10.1038/bjc.2017.10
   PubMed Web of Science ®Google Scholar
• Finn RS, Ahn DH, Javle MM, et al. Phase 1b investigation of the MEK inhibitor binimetinib in patients with advanced or metastatic biliary tract cancer. Invest New Drugs. 2018;36(6):1037–1043. doi:10.1007/s10637-018-0600-2
   PubMed Web of Science ®Google Scholar
• Kim JW, Lee KH, Kim JW, et al. Enhanced antitumor effect of binimetinib in combination with capecitabine for biliary tract cancer patients with mutations in the RAS/RAF/MEK/ERK pathway: phase Ib study. Br J Cancer. 2019;121(4):332–339. doi:10.1038/s41416-019-0523-5
   PubMed Web of Science ®Google Scholar
• Lowery MA, Bradley M, Chou JF, et al. Binimetinib plus gemcitabine and cisplatin Phase I/II Trial in patients with advanced biliary cancers. Clin Cancer Res. 2019;25(3):937–945. doi:10.1158/1078-0432.CCR-18-1927
   PubMed Web of Science ®Google Scholar
• Pacold ME, Suire S, Perisic O, et al. Crystal structure and functional analysis of Ras binding to its effector phosphoinositide 3-kinase gamma. Cell. 2000;103(6):931–943. doi:10.1016/S0092-8674(00)00196-3
   PubMed Web of Science ®Google Scholar
• Tuttle RL, Gill NS, Pugh W, et al. Regulation of pancreatic beta-cell growth and survival by the serine/threonine protein kinase Akt1/PKBalpha. Nat Med. 2001;7(10):1133–1137. doi:10.1038/nm1001-1133
   PubMed Web of Science ®Google Scholar
• Arcaro A, Guerreiro AS. The phosphoinositide 3-kinase pathway in human cancer: genetic alterations and therapeutic implications. Curr Genomics. 2007;8(5):271–306. doi:10.2174/138920207782446160
   PubMed Web of Science ®Google Scholar
• Manning BD, Cantley LC. AKT/PKB signaling: navigating downstream. Cell. 2007;129(7):1261–1274. doi:10.1016/j.cell.2007.06.009
   PubMed Web of Science ®Google Scholar
• Keniry M, Parsons R. The role of PTEN signaling perturbations in cancer and in targeted therapy. Oncogene. 2008;27(41):5477–5485. doi:10.1038/onc.2008.248
   PubMed Web of Science ®Google Scholar
• Chalhoub N, Baker SJ. PTEN and the PI3-kinase pathway in cancer. Annu Rev Pathol. 2009;4:127–150. doi:10.1146/annurev.pathol.4.110807.092311
   PubMed Web of Science ®Google Scholar
• Kim RD, Alberts SR, Peña C, et al. Phase I dose-escalation study of copanlisib in combination with gemcitabine or cisplatin plus gemcitabine in patients with advanced cancer. Br J Cancer. 2018;118(4):462–470. doi:10.1038/bjc.2017.428
   PubMed Web of Science ®Google Scholar
• Jin L, Jin MH, Nam AR, et al. Anti-tumor effects of NVP-BKM120 alone or in combination with MEK162 in biliary tract cancer. Cancer Lett. 2017;411:162–170. doi:10.1016/j.canlet.2017.10.002
   PubMed Web of Science ®Google Scholar
• McRee AJ, Sanoff HK, Carlson C, Ivanova A, O’Neil BH. A phase I trial of mFOLFOX6 combined with the oral PI3K inhibitor BKM120 in patients with advanced refractory solid tumors. Invest New Drugs. 2015;33(6):1225–1231. doi:10.1007/s10637-015-0298-3
   PubMed Web of Science ®Google Scholar
• Bendell JC, Rodon J, Burris HA, et al. Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors. J Clin Oncol. 2012;30(3):282–290. doi:10.1200/JCO.2011.36.1360
   PubMed Web of Science ®Google Scholar
• Hyman DM, Snyder AE, Carvajal RD, et al. Parallel phase Ib studies of two schedules of buparlisib (BKM120) plus carboplatin and paclitaxel (q21 days or q28 days) for patients with advanced solid tumors. Cancer Chemother Pharmacol. 2015;75(4):747–755. doi:10.1007/s00280-015-2693-z
   PubMed Web of Science ®Google Scholar
• Sakamoto Y, Yamagishi S, Tanizawa Y, Tajimi M, Okusaka T, Ojima H. PI3K-mTOR pathway identified as a potential therapeutic target in biliary tract cancer using a newly established patient-derived cell panel assay. Jpn J Clin Oncol. 2018;48(4):396–399. doi:10.1093/jjco/hyy011
   PubMed Web of Science ®Google Scholar
• Corti F, Nichetti F, Raimondi A, et al. Targeting the PI3K/AKT/mTOR pathway in biliary tract cancers: a review of current evidences and future perspectives. Cancer Treat Rev. 2019;72:45–55. doi:10.1016/j.ctrv.2018.11.001
   PubMed Web of Science ®Google Scholar
• Tanjak P, Thiantanawat A, Watcharasit P, Satayavivad J. Genistein reduces the activation of AKT and EGFR, and the production of IL6 in cholangiocarcinoma cells involving estrogen and estrogen receptors. Int J Oncol. 2018;53(1):177–188. doi:10.3892/ijo.2018.4375
   PubMed Web of Science ®Google Scholar
• Wilson JM, Kunnimalaiyaan S, Kunnimalaiyaan M, Gamblin TC. Inhibition of the AKT pathway in cholangiocarcinoma by MK2206 reduces cellular viability via induction of apoptosis. Cancer Cell Int. 2015;15(1):13. doi:10.1186/s12935-015-0161-9
   PubMedGoogle Scholar
• Ahn DH, Li J, Wei L, et al. Results of an abbreviated phase-II study with the Akt Inhibitor MK-2206 in patients with advanced biliary cancer. Sci Rep. 2015;5:12122. doi:10.1038/srep12122
   PubMed Web of Science ®Google Scholar
• Verzoni E, Pusceddu S, Buzzoni R, et al. Safety profile and treatment response of everolimus in different solid tumors: an observational study. Future Oncol. 2014;10(9):1611–1617. doi:10.2217/fon.14.31
   PubMed Web of Science ®Google Scholar
• Costello BA, Borad MJ, Qi Y, et al. Phase I trial of everolimus, gemcitabine and cisplatin in patients with solid tumors. Invest New Drugs. 2014;32(4):710–716. doi:10.1007/s10637-014-0096-3
   PubMed Web of Science ®Google Scholar
• Buzzoni R, Pusceddu S, Bajetta E, et al. Activity and safety of RAD001 (everolimus) in patients affected by biliary tract cancer progressing after prior chemotherapy: a phase II ITMO study. Ann Oncol. 2014;25(8):1597–1603. doi:10.1093/annonc/mdu175
   PubMed Web of Science ®Google Scholar
• Kim ST, Lee J, Park SH, et al. Prospective phase II trial of everolimus in PIK3CA amplification/mutation and/or PTEN loss patients with advanced solid tumors refractory to standard therapy. BMC Cancer. 2017;17(1):211. doi:10.1186/s12885-017-3196-6
   PubMedGoogle Scholar
• Lau DK, Tay RY, Yeung YH, et al. Phase II study of everolimus (RAD001) monotherapy as first-line treatment in advanced biliary tract cancer with biomarker exploration: the RADiChol Study. Br J Cancer. 2018;118(7):966–971. doi:10.1038/s41416-018-0021-1
   PubMed Web of Science ®Google Scholar
• Rizell M, Andersson M, Cahlin C, Hafström L, Olausson M, Lindnér P. Effects of the mTOR inhibitor sirolimus in patients with hepatocellular and cholangiocellular cancer. Int J Clin Oncol. 2008;13(1):66–70. doi:10.1007/s10147-007-0733-3
   PubMed Web of Science ®Google Scholar
• Jung KS, Lee J, Park SH, et al. Pilot study of sirolimus in patients with PIK3CA mutant/amplified refractory solid cancer. Mol Clin Oncol. 2017;7(1):27–31. doi:10.3892/mco.2017.1272
   PubMedGoogle Scholar
• Zhang KS, Zhou Q, Wang YF, Liang LJ. Inhibition of Wnt signaling induces cell apoptosis and suppresses cell proliferation in cholangiocarcinoma cells. Oncol Rep. 2013;30(3):1430–1438. doi:10.3892/or.2013.2560
   PubMed Web of Science ®Google Scholar
• Shinada K, Tsukiyama T, Sho T, Okumura F, Asaka M, Hatakeyama S. RNF43 interacts with NEDL1 and regulates p53-mediated transcription. Biochem Biophys Res Commun. 2011;404(1):143–147. doi:10.1016/j.bbrc.2010.11.082
   PubMed Web of Science ®Google Scholar
• Loregger A, Grandl M, Mejías-Luque R, et al. The E3 ligase RNF43 inhibits Wnt signaling downstream of mutated β-catenin by sequestering TCF4 to the nuclear membrane. Sci Signal. 2015;8(393):ra90. doi:10.1126/scisignal.aac6757
   PubMed Web of Science ®Google Scholar
• Ong CK, Subimerb C, Pairojkul C, et al. Exome sequencing of liver fluke-associated cholangiocarcinoma. Nat Genet. 2012;44(6):690–693. doi:10.1038/ng.2273
   PubMed Web of Science ®Google Scholar
• Rizzo A, Ricci AD, Tavolari S, Brandi G. Circulating tumor DNA in biliary tract cancer: current evidence and future perspectives. Cancer Genomics Proteomics. 2020;17(5):441–452. doi:10.21873/cgp.20203
   PubMed Web of Science ®Google Scholar
• Ettrich TJ, Schwerdel D, Dolnik A, et al. Genotyping of circulating tumor DNA in cholangiocarcinoma reveals diagnostic and prognostic information. Sci Rep. 2019;9(1):13261. doi:10.1038/s41598-019-49860-0
   PubMed Web of Science ®Google Scholar